Genetic Determinants of the Hypokalemic and Hyperglycemic Effect of Albuterol Inhalation - Full Text View

Purpose

Several studies have indicated that albuterol administered either intravenously or by inhalation can significantly reduce plasma potassium concentration in patients suffering from chronic renal failure.In conjunction with the decrease in potassium concentration a modest rise in glucose concentration is usually noted. These metabolic effects are characterized by rapid onset occurring as early as 3-5 minutes following salbutamol administration and lasting for at least 1 hour.

The role played by ß2AR polymorphisms in determining the bronchial and vascular response to ß2AR agonist drugs, have been confirmed by several studies.

The purpose of the present study is to examine possible causal relationships between genetically based alteration in the structure of ß2AR and the metabolic effects of inhaled albuterol.

Condition	Intervention
Hyperkalemia Chronic Renal Failure	Drug: Albuterol (1,200 μg) through metered-dose inhaler

MedlinePlus related topics:

Kidney Failure

ChemIDplus related topics:

Dextrose Albuterol sulfate Albuterol Levalbuterol hydrochloride Levalbuterol tartrate Potassium chloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Pharmacokinetics/Dynamics Study

Official Title:	Evaluation of β2 Genetic Polymorphisms and the Effect of Albuterol Inhalation on Potassium and Glucose Plasma Concentration

Further study details as provided by Hadassah Medical Organization:

Primary Outcome Measures:

The extent of decrease in plasma potassium concentration
The extent of increase in plasma glucose concentration
Plasma concentration of albuterol

Estimated Enrollment:	150
Study Start Date:	August 2002

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

patients regularly attending the nephrological clinic or the dialysis unit
persistent potassium concentration above 5 mEq/L

Exclusion Criteria:

Patients suffering from active ischemic heart disease
Patient with a recent history of arrhythmia
Patients treated regularly with ß blockers
Patients treated regularly with salbutamol or other ß2AR agonists
Patients suffering from persistent tachycardia (pulse > 100 beats/min)
Patients who are hemodynamically unstable
Patients suffering from any acute illness

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00162487

Locations


Israel
	Hadassah Medical Organization	Recruiting
	Jerusalem, Israel, 91120
	Contact: Arik Tzukert, DMD 00 972 2 6776095 arik@hadassah.org.il
	Contact: Hadas Lemberg, PhD 00 972 2 6777572 lhadas@hadassah.org.il
	Principal Investigator: Yoseph Caraco, MD

Sponsors and Collaborators

Hadassah Medical Organization

Investigators


Principal Investigator:	Yoseph Caraco, MD	Hadassah Medical Organization

More Information

Study ID Numbers:	yc19556-HMO-CTIL
First Received:	September 11, 2005
Last Updated:	March 17, 2008
ClinicalTrials.gov Identifier:	NCT00162487
Health Authority:	Israel: Israeli Health Ministry Pharmaceutical Administration

Study placed in the following topic categories:

Renal Insufficiency

Metabolic Diseases

Urologic Diseases

Renal Insufficiency, Chronic

Albuterol

Kidney Failure, Chronic

Hyperkalemia

Water-Electrolyte Imbalance

Kidney Diseases

Metabolic disorder

Kidney Failure

Additional relevant MeSH terms:

Respiratory System Agents

Neurotransmitter Agents

Molecular Mechanisms of Pharmacological Action

Adrenergic beta-Agonists

Adrenergic Agents

Physiological Effects of Drugs

Anti-Asthmatic Agents

Reproductive Control Agents

Pharmacologic Actions

Adrenergic Agonists

Tocolytic Agents

Autonomic Agents

Therapeutic Uses

Peripheral Nervous System Agents

Bronchodilator Agents

ClinicalTrials.gov processed this record on September 19, 2008

Sponsored by:	Hadassah Medical Organization
Information provided by:	Hadassah Medical Organization
ClinicalTrials.gov Identifier:	NCT00162487